Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with additional cardiovascular risk factors, can significantly reduce heart ...

Kidney disease is a growing health concern in Australia, with many people unaware that they are affected. According to ...

The dual SGLT1/2 inhibitor sotagliflozin (Inpefa) reduced the risk for myocardial infarction (MI) and stroke in high-risk ...

Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with additional cardiovascular risk factors, can significantly reduce heart ...

In a powerful act of love and sacrifice, Julie Malliet donated her kidney to her husband, Dave, who had been battling chronic kidney disease for years.

Cardiovascular diseases claim more lives in the U.S. than all forms of cancer and accidental deaths combined, according to ...

Raising taxes on alcohol and tobacco is a viable financing model to combat lifestyle diseases, as the high cost of treatment continues to burden low-income individuals suffering from non-communicable ...

A popular diabetes drug just got a major new approval — and it could be a game-changer for millions of Americans at risk for kidney failure.

Observational data fill a knowledge gap in the absence of randomized trials comparing empagliflozin vs dapagliflozin in patients with type 2 diabetes.

Humana and Monogram Health, a value-based multispecialty provider of in-home care and benefit management services for patients living with kidney disease, have expanded their partnership to patients ...

Study led by Mount Sinai researcher shows sotagliflozin is the only drug in its class to demonstrate these results ...

These drugs, called GLP1-RAs (short for glucagon-like peptide-1 receptor agonists), have been found to reduce hospital visits ...